BMS-986020 sodium

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H25N2O5.Na
Molecular Weight	504.509
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].C[C@@H](OC(=O)NC1=C(ON=C1C)C2=CC=C(C=C2)C3=CC=C(C=C3)C4(CC4)C([O-])=O)C5=CC=CC=C5

InChI

InChIKey=QDCOVTLBRMPIMY-FSRHSHDFSA-M

InChI=1S/C29H26N2O5.Na/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33;/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33);/q;+1/p-1/t19-;/m1./s1

HIDE SMILES / InChI

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Lysophosphatidic acid receptor Edg-2 4 Target ID: CHEMBL3819 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25499971	Antagonist 2849		8.9 null [pIC50]

PubMed

Title	Date	PubMed
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.	2018-11	30201408
Lysophospholipid receptors in drug discovery.	2015-05-01	25499971

Patents

Name

Type

Language

BMS-986020 sodium

Common Name

English

Cyclopropanecarboxylic acid, 1-[4?-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1?-biphenyl]-4-yl]-, sodium salt (1:1)

Preferred Name

English

Sodium 1-(4-{4-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]phenyl}phenyl)cyclopropane-1-carboxylate

Systematic Name

English

Code System Code Type Description

FDA UNII

D7YP9R1CG0

Created by admin on Mon Mar 31 19:30:14 GMT 2025 , Edited by admin on Mon Mar 31 19:30:14 GMT 2025

PRIMARY

PUBCHEM

132274336

Created by admin on Mon Mar 31 19:30:14 GMT 2025 , Edited by admin on Mon Mar 31 19:30:14 GMT 2025

PRIMARY

CAS

1380650-53-2

Created by admin on Mon Mar 31 19:30:14 GMT 2025 , Edited by admin on Mon Mar 31 19:30:14 GMT 2025

PRIMARY

ACTIVE MOIETY


					38CTP01B4L

BMS-986020

SUBSTANCE RECORD


					D7YP9R1CG0

BMS-986020 sodium